22367-76-6

Usage

Uses

Used in Pharmaceutical Industry:
3-(2-Hydroxyphenyl)propionamide is used as a pharmaceutical intermediate for its potential role in the modulation of pain and inflammation. It is considered a promising candidate for the development of therapeutic medications due to its ability to influence biological processes related to pain and inflammatory responses.
Used in Organic Synthesis:
3-(2-Hydroxyphenyl)propionamide is used as an intermediate in organic synthesis, contributing to the production of various chemical compounds. Its unique structure and properties make it a valuable component in the synthesis of a range of organic molecules, enhancing the versatility and applicability of chemical reactions.
Used in Chemical Compound Production:
As a raw material, 3-(2-Hydroxyphenyl)propionamide is utilized in the production of various chemical compounds. Its presence in the synthesis process allows for the creation of diverse chemical entities, broadening the scope of chemical applications and industries that can benefit from its inclusion.

InChI:InChI=1/C9H11NO2/c10-9(12)6-5-7-3-1-2-4-8(7)11/h1-4,11H,5-6H2,(H2,10,12)

Upstream product

• 20921-04-4 ethyl 3-(2-hydroxyphenyl)propanoate 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 
• 495-78-3 3-(2-hydroxyphenyl)propionic acid 
• 91-64-5 coumarin 
• 100981-05-3 5-[bis(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 59734-18-8 3-(2-methoxy-phenyl)-propionic acid amide 

Downstream Products

• 2039-66-9 o-tyramine 
• 7664-41-7 ammonia 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 
• 627097-21-6 tert-Butyl 2-[2-(2-aminocarbonylethyl)phenoxy]-2-methylpropionate 
• 59577-12-7 3-(2-acetoxy-phenyl)-propionitrile 
• 59577-13-8 3-(2-hydroxyphenyl)propanenitrile 
• 59577-11-6 3-(2-acetoxy-phenyl)-propionic acid amide 

Relevant academic research and scientific papers

Mechanochemical Synthesis of Primary Amides

Ball milling of aromatic, heteroaromatic, vinylic, and aliphatic esters with ethanol and calcium nitride afforded the corresponding primary amides in a transformation that was compatible with a variety of functional groups and maintained the integrity of a stereocenter α to carbonyl. This methodology was applied to α-amino esters and N-BOC dipeptide esters and also to the synthesis of rufinamide, an antiepileptic drug.

Amidation of esters assisted by Mg(OCH3)2 or CaCl2

Magnesium methoxide (Mg(OCH3)2) and calcium chloride have been shown to facilitate the direct aminolysis of esters by ammonia to primary amides. Methyl, ethyl, isopropyl, and tert-butyl esters were converted to the corresponding carboxamides in good yields. Reactions have been run on a larger scale and without the safety liability inherent in the use of magnesium nitride (Mg3N2). Ammonium chloride and amine hydrochlorides have been used successfully in the place of ammonia with magnesium methoxide.

Magnesium nitride as a convenient source of ammonia: Preparation of primary amides

(Chemical Equation Presented) The use of magnesium nitride (Mg 3N2) as a convenient source of ammonia has been explored for the direct transformation of esters to primary amides. Methyl, ethyl, isopropyl, and tert-butyl esters are converted to the corresponding carboxamides in good yields (75-99%).

Benzoxazole compound and pharmaceutical composition containing the same

The present invention is directed to a benzoxazole compound represented by the following formula (1): (wherein R1represents an alkyl group, a C6-10aryl-C1-8alkyl group, etc.; each of R2and R3, which a

Therapeutic morpholino-substituted compounds

Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

Quantitative solid-state reactions of amines with carbonyl compounds and isothiocyanates

A series of solid-state reactions is reported of gaseous or solid amines with aldehydes to give imines, with solid anhydrides to give diamides (therefrom imides) or amidic carboxylic salts or imides, with solid imides to give diamides, with solid lactones or carbonates to give functionalized carbamic esters, with polycarbonates to give degradative aminolysis, and with solid isothiocyanates to give thioureas. Diamides give imides by solid-state thermolysis or acid catalysis. Various double, two-step, 3-cascade, and sequential reactions are reported in the solid state without melting. The yields are quantitative in 53 reported reaction examples and no workup (except for washings in four cases) is required in the 100% yield reactions. Three initially solid-state reactions but with liquid product were not quantitative. An upscaling to the kg scale shows promise of the technique for large scale applications. Supermicroscopic analyses with AFM elucidate the solid-state mechanism by virtue of far-reaching anisotropic molecular movements in three-step processes. Gas-solid aminolyses of polycarbonates are also studied with AFM. The implications to sustainable chemistry are discussed. (C) 2000 Elsevier Science Ltd.